Epinephrine Injection, 1mg/mL recall — Fresenius Kabi Usa, LLC (Class III)

Fresenius Kabi Usa, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Epinephrine Injection, 1mg/mL — a Class III recall, initiated 2026-05-14 and posted to the FDA enforcement report on 2026-06-17, under recall number D-0581-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed Impurities/Degradations Specifications”. From the product description, the form is injection, the strengths given are 1mg/mL and 1 mL and it is marked Rx only. 2 National Drug Code numbers are printed in the record: 63323-696-02 and 63323-696-25. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in IL, United States. It is the only recall number the FDA has filed under event ID 98997. Fresenius Kabi Usa, LLC accounts for 6 recall records in the indexed dataset. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0581-2026
FDA event ID 98997
Classification Class III (least serious regulatory tier)
Status Ongoing
Recalling firm Fresenius Kabi Usa, LLC
Recall initiated 2026-05-14
Reported by FDA 2026-06-17
Report lag 34 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record IL, United States
Product description (source) Epinephrine Injection, USP, 1mg/mL, 1 mL single-dose vial, Rx only, Fresenius Kabi, Lake Zurich, IL 60047, NDC 63323-696-02 (vial), NDC 63323-696-25 (carton)

Reason reported by FDA

Failed Impurities/Degradations Specifications

3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 22-word product description above; each is a literal substring of it.

Product named Epinephrine Injection
Form Injection
Strength 1mg/mL · 1 mL
NDC 63323-696-02 · 63323-696-25
Marketing category Rx only

Other indexed recalls from Fresenius Kabi Usa, LLC

6 indexed records name Fresenius Kabi Usa, LLC as the recalling firm, across 2 FDA events, reported 2026-06-17 to 2026-07-29. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Glycopyrrolate Injection, 1 mgD-0725-2026Class II1 mg · Injection2026-07-29
Lidocaine HCl Injection, 2%D-0726-2026Class II2% · Injection2026-07-29
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%D-0727-2026Class II0.5% · Injection2026-07-29
Xylocaine (lidocaine HCl Injection, USP), 1%D-0728-2026Class II1% · Injection2026-07-29
Xylocaine (lidocaine HCl Injection, USP), 1%D-0729-2026Class II1% · Injection2026-07-29

Reported in the same month (2026-06)

74 enforcement reports carry a report date in 2026-06; these 5 are the Class III ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Primidone Tablets, 50 mgD-0585-2026Amneal Pharmaceuticals, LLCClass III2026-06-17
Lidocaine HCl Injection, 2%D-0552-2026Eugia US LLCClass III2026-06-10
Focalin XR (dexmethylphenidate HCl) 5 mgD-0608-2026Sandoz IncClass III2026-06-24
Nicotine Transdermal System Patch, 14 mgD-0550-2026Aveva Drug Delivery Systems, Inc.Class III2026-06-03
PRED MILD, 0.12%D-0551-2026Abbvie Inc.Class III2026-06-03

Nearest Class III recalls by date

25 of 250 indexed records share the Class III tier; the 6 nearest to 2026-06-17 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mLD-0619-2026Ani Pharmaceuticals, Inc.10 mg/5 mL · Oral Solution2026-07-01
Primidone Tablets USP, 250mgD-0533-2026Lannett Company Inc.250mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0534-2026Golden State Medical Supply Inc.50 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0535-2026Golden State Medical Supply Inc.250 mg · Tablets2026-05-27
Primidone Tablets, 250 mgD-0536-2026Amerisource Health Services LLC250 mg · Tablets2026-05-27
Primidone Tablets, 50 mgD-0537-2026Amerisource Health Services LLC50 mg · Tablets2026-05-27

Reading this record

Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 63323-696-02 and 63323-696-25 at the FDA source to confirm it is covered.

Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Fresenius Kabi Usa, LLC (6 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0581-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0581-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-06-17
Ingested
2026-08-22
Record hash
d7938b17ae08b675

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.